



A



Patients at risk

| | | | | | | | | |
|--------|-----|-----|-----|-----|-----|-----|----|----|
| — ALK | 16 | 14 | 13 | 13 | 12 | 8 | 1 | 0 |
| — EGFR | 219 | 198 | 193 | 171 | 146 | 98 | 55 | 16 |
| — KRAS | 421 | 385 | 343 | 302 | 248 | 179 | 79 | 12 |

B



Patients at risk

| | | | | | | | | |
|--------|----|----|----|----|----|---|---|---|
| — ALK | 13 | 11 | 6 | 6 | 2 | 2 | 1 | 0 |
| — EGFR | 36 | 34 | 29 | 21 | 14 | 7 | 3 | 1 |
| — KRAS | 59 | 47 | 33 | 24 | 15 | 9 | 2 | 0 |